TY - JOUR
KW - Analgesics, Opioid/therapeutic use
KW - Buprenorphine/therapeutic use
KW - Delayed-Action Preparations/therapeutic use
KW - Humans
KW - Methadone/therapeutic use
KW - Naltrexone/therapeutic use
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/drug therapy/epidemiology
KW - United States/epidemiology
KW - Extended-release buprenorphine
KW - Medication for opioid use disorder
KW - opioid use disorder
KW - Retention
AU - J. R. Morgan
AU - A . Y. Walley
AU - S. M. Murphy
AU - A. Chatterjee
AU - S. E. Hadland
AU - J. Barocas
AU - B. P. Linas
AU - S. A. Assoumou
A1 - 
AD - Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, MA, USA. Electronic address: jakem@bu.edu.; Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.; Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.; Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.; Grayken Center for Addiction, Division of General Pediatrics, Department of Medicine, Boston Medical Center, Boston, MA, USA; Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA.; Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.; Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.; Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, USA.
BT - Drug and alcohol dependence
C5 - Financing & Sustainability; Healthcare Disparities; Opioids & Substance Use
CY - Ireland
DO - 10.1016/j.drugalcdep.2021.108764
JF - Drug and alcohol dependence
LA - eng
M1 - Journal Article
PB - Elsevier B.V
PP - Ireland
PY - 2021
SN - 1879-0046; 0376-8716
SP - 108764
T1 - Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort
T2 - Drug and alcohol dependence
TI - Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort
U1 - Financing & Sustainability; Healthcare Disparities; Opioids & Substance Use
U2 - 34051547
U3 - 10.1016/j.drugalcdep.2021.108764
VL - 225
VO - 1879-0046; 0376-8716
Y1 - 2021
Y2 - Aug 1
ER -